Wpisz informacje, które znasz





Palgrave Macmillan UK


713,96 PLN
Wysyłamy w 28 dni

Opis produktu

This is the first book to examine how effectively American and supranational EU governments have regulated innovative pharmaceuticals during the last 30 years regarding public health. It explains why pharmaceutical regulation has been misdirected by commercial interests and misconce1. Putting Pharmaceutical Regulation to the Test: A Social Science for Public Health 2. The Political Economy of Innovative Drug Regulation in the NeoLiberal Era 3. Designs on Diabetes Drugs 4. Desperate Regulation for Desperate Cancer Patients 5. The Making of a Harmful Therapeutic Breakthrough 6. The Regulatory Science and Politics of Risk Management 7. Conclusions and Pol''Precisely 50 years have passed since the first truly modern system of medicines regulation came into operation in The Netherlands. That is a good reason to take stock of what drug regulation has achieved in half a century and where it has perhaps failed to serve society optimally. Courtney Davis and John Abraham have now done precisely that in a thoughtful and independent study of developments on both sides of the Atlantic. Their findings make clear the extent to which empty rhetoric from every direction (emanating most loudly from industrys puppet organizations and from neoliberal politicians or think tanks) has been allowed to dominate the debate. This book is so solidly documented that it does not make for easy reading but that reading will be rewarded. If in the coming years society is to rethink these matters to identify truly valid interests in the pharmaceutical field and to strike a fair balance betweenthem with the genuine needs of the individual consumer and patient ever in the foreground'/'''this is the way to do it. Graham Dukes External Professor of Drug Policy Studies University of Oslo Norway'/'''Davis and Abraham provide new insights into how the neoliberal regime that has developed since the 1980s has profoundly biased the way the Food and Drug Administration and the European Medicines Agency deal with drug approvals and safety to the detriment of the patients they are supposed to be protecting. The drug companies not the people who need effective and safe medicines are now the primary clients of drug regulators. However Davis and Abraham do not stop with just criticizing the current situation: they offer concrete steps that can be taken to restore drug regulation to what should be its true function. This book should be the starting point for anyone interested in understanding the forces that are shaping the medicines we take. Joel Lexchin Professor of Health Policy York University Canada'/'''This extremely wellresearched book serves the dual purpose of collating the decades of work carried out by Davis and Abraham and laying the foundation for a new social science discipline concerned with pharmaceuticals and public health policy. The book'/'''outlines how a collection of theoretical tools that is neoliberal theory capture theory corporate bias theory diseasepolitics theory (hard

Wymiary: 5219 gr 140 mm 216 mm

Dodaj recenzję

Zaloguj sie, aby móc dodać swoją recenzję.


mail: prus@prus24.pl

telefon: (22) 826-18-35

Copyright © 2001-2019 Główna Księgarnia Naukowa im. B. Prusa. Wszelkie prawa zastrzeżone.
Home   /   Informacje   /   Kontakt
Projekt i realizacja: